Tripartite motif 8 (TRIM8), an E3 ligase ubiquitously expressed in various cells, is closely involved in innate immunity. However, its role in nonalcoholic steatohepatitis is largely unknown. Here, we report evidence that TRIM8 is a robust enhancer of steatohepatitis and its complications induced by a high-fat diet or a genetic deficiency (ob/ob). Using gain-offunction and loss-of-function approaches, we observed dramatic exacerbation of insulin resistance, hepatic steatosis, inflammation, and fibrosis by hepatocyte-specific TRIM8 overexpression, whereas deletion or down-regulation of TRIM8 in hepatocytes led to a completely opposite phenotype. Furthermore, investigations of the underlying mechanisms revealed that TRIM8 directly binds to and ubiquitinates transforming growth factor-beta-activated kinase 1, thus promoting its phosphorylation and the activation of downstream c-Jun N-terminal kinase/p38 and nuclear factor jB signaling. Importantly, the participation of TRIM8 in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis was verified on the basis of its dramatically increased expression in the livers of these patients, suggesting a promising development of TRIM8 disturbance for the treatment of nonalcoholic steatohepatitis-related metabolic disorders. Conclusion: The E3 ligase TRIM8 is a potent regulator that exacerbates steatohepatitis and metabolic disorders dependent on its binding and ubiquitinating capacity on transforming growth factor-beta-activated kinase 1. (HEPATOLOGY 2017;65:1492-1511 N onalcoholic steatohepatitis (NASH), characterized by lipid accumulation and inflammation in the liver, contributes to a broad spectrum of severe pathologies, ranging from metabolic syndrome to hepatocellular carcinoma.
N onalcoholic steatohepatitis (NASH), characterized by lipid accumulation and inflammation in the liver, contributes to a broad spectrum of severe pathologies, ranging from metabolic syndrome to hepatocellular carcinoma. (1, 2) The everincreasing incidence of NASH has placed it as the predicted leading cause of liver transplantation in the next decade. However, no pharmacological approach is available for its clinical treatment due to our poor understanding of its complex pathogenesis. (3) (4) (5) Tripartite motif 8 (TRIM8) is a ubiquitously expressed factor in the TRIM family that orchestrates Abbreviations: Ad, adenoviral; Adsh, adenoviral short hairpin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; cDNA, complementary DNA; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GFP, green fluorescent protein; G6Pase, glucose 6-phosphatase; GTT, glucose tolerance test; HA, hemagglutinin; HFD, high-fat diet; HOMA-IR, homeostatic model assessment of the insulin resistance; IKKb, inhibitor of NF-jB kinase subunit b; IL, interleukin; IP, immunoprecipitation; IRS, insulin receptor substrate; ITT, insulin tolerance test; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; NASH, nonalcoholic steatohepatitis; NC, normal chow; NEFA, nonesterified fatty acid; NF-jB, nuclear factor jB; NTG, nontransgenic; 5Z-7-OX, 5Z-7-Oxozeaenol; PEPCK, phosphoenolpyruvate carboxykinase; TAK1, transforming growth factor-beta-activated kinase 1; TC, total cholesterol; TG, triglyceride; TRIM8, tripartite motif 8; TRIM8-HKO, hepatocyte-specific TRIM8-knockout; TRIM8-HTG, hepatocyte-specific TRIM8 transgenic. multiple biological processes, including cell survival, differentiation, apoptosis, and, in particular, the innate immune response. (6) (7) (8) Harboring a conserved RBCC motif composed of a RING domain followed by 2 Bbox and a coiled-coil domain at the N terminus, TRIM8 possesses E3 ligase activity. (9) Previous studies of this factor and its family members have mainly focused on their participation in cancer and immune diseases deriving from their potent regulation of inflammation. (8, (10) (11) (12) Given the close involvement of inflammation in NASH, (13) we hypothesized that TRIM8 might be critical for the pathogenesis of steatohepatitis and related metabolic disorders; however, this hypothesis and associated underlying mechanisms remain to be tested.
In the present study, we performed in vivo and in vitro experiments to test our hypothesis regarding the function of TRIM8 in steatohepatitis and its complications. Employing gain-of-function and loss-offunction approaches, we found that TRIM8 exacerbated high-fat diet (HFD)-induced or gene deficiency (ob/ob)-induced insulin resistance, hepatic lipid accumulation, inflammation, and fibrosis through binding to and ubiquitinating transforming growth factorbeta-activated kinase 1 (TAK1).
Materials and Methods

ANIMALS AND TREATMENTS
TRIM8
flox/flox (TRIM8-flox) mice were created using the CRISPR/Cas9 system, (14) which were then crossed with Albumin-Cre mice (Jackson Laboratory, Bar Harbor, ME) to obtain hepatocyte-specific TRIM8-knockout mice (TRIM8-HKO). Constructs containing full-length TRIM8 complementary DNA (cDNA) were inserted after CAG-loxp-CAT-loxp cassettes, which were microinjected into fertilized C57BL/6J embryos to generate conditional hepatocyte-specific TRIM8 overexpressing mice. The generated mice were crossed with Albumin-Cre mice to obtain hepatocyte-specific TRIM8 transgenic (TRIM8-HTG) mice. To knock down the expression of TRIM8 in ob/ob mice, adenoviral short hairpin (Adsh) TRIM8 (5 3 10 9 pfu) was injected at the age of 8 weeks after normal chow (NC) diet administration. The ob/ob mice injected with AdshRNA were used as controls for the AdshTRIM8-treated mice. AdTRIM8, AdTRIM8-M (an adenovirus-encoding mutant TRIM8 lacking the TAK1-binding domain [59-182]), and AdTRIM8(C15A; C18A) were injected into C57BL/6J mice to overexpress TRIM8 or its indicated mutants, respectively. Mice injected with adenoviral green fluorescent protein (AdGFP) were used as controls. 5Z-7-Oxozeaenol (5 mg/kg; 5Z-7-OX, O9890-1 MG; Sigma, St. Louis, MO) was intraperitoneally administered into nontransgenic (NTG) and TRIM8-overexpressing mice in parallel to specifically inhibit TAK1 activation.
A mouse NASH model was established through feeding mice an HFD (60% kcal from fat; D-12492; Research Diets, NJ) for 12 weeks starting at the age of 8-10 weeks, whereas NC-fed mice were maintained on a rodent diet with 10% kcal from fat (D-12450B). Food and water were provided ad libitum. Mice were housed in a standard environment with a 12-hour light/12-hour dark cycle. Body weights, fasting blood glucose levels, and fasting insulin levels were recorded every 2 weeks. All of the animal experiments were approved by the Animal Care and Use Committee of Renmin Hospital at Wuhan University, and care was provided according to the criteria outlined in the Guide
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for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences and published by the National Institutes of Health.
HUMAN LIVER SAMPLES
Human liver samples including nonsteatosis and steatohepatitis were collected from Renmin Hospital of Wuhan University. Written informed consent was signed by the subjects or by the families of the liver donors. Procedures involving human samples were approved by the Renmin Hospital of Wuhan University Review Board and were consistent with the principles outlined in the Declaration of Helsinki.
METABOLIC PARAMETER ANALYSIS
Fasting blood glucose levels, fasting serum insulin levels, homeostatic model assessment of insulin resistance (HOMA-IR) values, glucose tolerance tests (GTTs), and insulin tolerance tests (ITTs) were examined and performed as described. (15) 
HISTOLOGICAL ANALYSES AND IMMUNOHISTOCHEMISTRY
Oil red O staining and hematoxylin and eosin staining were performed on frozen and paraffin-embedded liver sections, respectively. Periodic acid-Schiff staining was performed to detect glycogen as reported. (15) Histological fibrosis was examined by sirius red and alpha-smooth muscle actin staining. The expression and localization of TRIM8 were investigated by immunohistochemistry.
LIVER LIPID AND FUNCTION ASSAYS
Triglyceride (TG), total cholesterol (TC), and nonesterified fatty acid (NEFA) levels were detected in liver samples using commercial kits (Wako, Osaka, Japan), while serum levels of alanine amino transferase (ALT), aspartate amino transferase (AST), and alkaline phosphatase (ALP) were measured using an ADVIA 2400 Chemistry System analyzer (Siemens, Tarrytown, NY) according to the manufacturer's instructions to evaluate the liver function of the mice.
PRIMARY HEPATOCYTE ISOLATION, CULTURE, AND TREATMENT
Primary hepatocytes were isolated from 6-week-old to 8-week-old male mice using a liver perfusion approach, as described. (16) Hepatocytes were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin in a 5% CO 2 /water-saturated incubator at 378C.
QUANTITATIVE REAL-TIME PCR
After total mRNA isolation and cDNA synthesis, PCR amplification was performed with the SYBR Green PCR Master Mix (04887352001; Roche). The mRNA expression levels of the target genes were normalized to the expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
WESTERN BLOT ANALYSIS
For western blotting, total protein samples were extracted from tissue or cell samples and 30 lg of protein samples were separated on a 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis gel (and transferred to a polyvinylidene fluoride membrane). Protein expression was visualized by incubating primary antibodies (Supporting Table S2 ) overnight at 48C, followed by the corresponding secondary antibodies.
PLASMID CONSTRUCTS
The entire mouse TRIM8 coding region was cloned into pcDNA5-HA-C1 and psi-Flag-C1 plasmids to generate the pcDNA5-HA-TRIM8 and psi-Flag-TRIM8 recombinant plasmids. TRIM8 truncations were obtained by PCR amplification of psi-Flag-TRIM8 using corresponding primer pairs. The pcDNA5-HA-TAK1, pcDNA5-Flag-TAK1, and Flag-labeled TAK1 truncations were constructed as described. (17) 
IMMUNOPRECIPITATION AND IN VIVO UBIQUITINATION ASSAYS
Immunoprecipitation (IP) assays were performed as described in previous studies to identify the binding capacity and domain of TRIM8 that binds to TAK1. (18) Ubiquitination assays were performed as described. (19) YAN, ZHANG, ET AL.
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STATISTICAL ANALYSIS
Statistical analyses were performed using SPSS software (version 13.0), and all data are expressed as means 6 standard deviations. Statistical differences among more than 2 groups were compared using a one-way analysis of variance, followed by Bonferroni's post hoc tests (assuming equal variances) or Tamhane's T2 post hoc tests. Student t tests were performed to compare the differences between two groups. P < 0.05 was considered significant.
ADDITIONAL METHODS
Detailed methods are provided in the Supporting Information.
Results
HEPATIC TRIM8 EXPRESSION IS INCREASED IN STEATOTIC LIVERS
Our hypothesis on the potential regulation of TRIM8 in hepatic steatosis was first tested by examining variations in the expression of the TRIM8 protein in fatty livers. The TRIM8 protein level was dramatically increased in the livers from patients with steatosis and steatohepatitis compared with nonsteatotic controls, with the highest expression level in the steatohepatitis group (steatohepatitis > steatosis > nonsteatosis) (Fig.  1A) . A mouse model of hepatic steatosis was established through feeding an HFD for 12 weeks to investigate the relationship between TRIM8 and steatohepatitis, and TRIM8 expression was measured in liver samples from these mice. Consistent with our observations in human samples, the expression of TRIM8 in the livers of HFD-fed mice was significantly increased compared with its expression in NC-fed controls (Fig. 1B) . Increased TRIM8 expression was also observed in the livers of ob/ob mice (Fig. 1C) . In primary hepatocytes, expression of TRIM8 protein was significantly increased after palmitate challenge compared with the control group (Fig. 1D) . Immunohistochemistry on liver sections further confirmed the significant elevation of TRIM8 in the livers of mice upon HFD treatment (Fig. 1E ). However, the mRNA level of TRIM8 was not significantly changed in fatty livers or in palmitate-stimulated primary hepatocytes, suggesting that the up-regulated TRIM8 protein level in fatty liver was not due to the changed transcriptional level (Supporting Fig. S1 ). The consistent increase in TRIM8 expression in livers of nonalcoholic fatty liver disease/NASH patients and in the mouse NASH model induced by different stimuli suggests a potential regulatory effect of TRIM8 on steatohepatitis.
HEPATIC TRIM8 OVEREXPRESSION EXACERBATES HFD-INDUCED INSULIN RESISTANCE
Considering the dramatic increase in TRIM8 expression in fatty livers, we generated hepatocyte-specific TRIM8-overexpressing mice ( Fig. 2A) to evaluate the role of increased TRIM8 expression in the pathogenesis of NASH and related metabolic disorders. With HFD consumption, the body weights, fasting blood glucose levels, and insulin levels of NTG and TRIM8-HTG mice were rapidly increased compared to the NCtreated controls, and the fasting blood glucose and insulin levels in TRIM8-HTG mice were much higher than those in the NTG littermates from 2 to 12 weeks of HFD administration ( Fig. 2B-D) . Correspondingly, HOMA-IR values were markedly increased by TRIM8 overexpression (Fig. 2E ). TRIM8-HTG mice exhibited significantly higher glucose concentrations and areas under the curve in GTT and ITT assays, indicating that TRIM8 compromised insulin sensitivity ( , and glycogen synthase kinase 3b in the TRIM8-HTG group (Fig. 2H) . Additionally, the glycogen content in the TRIM8-HTG group was much lower than in NTG control mice after HFD treatment (Fig. 2I) , accompanied by marked increases in phosphoenolpyruvate carboxykinase (PEPCK) and the catalytic subunit of glucose 6-phosphatase (G6Pase) mRNA and protein levels (Fig. 2J,K) . Together, these results reveal that overexpression of TRIM8 in the liver exacerbates insulin resistance and glucose metabolism dysregulation induced by an HFD.
TRIM8 DEFICIENCY IN THE LIVER INHIBITS INSULIN RESISTANCE INDUCED BY AN HFD
To further validate the functional role of TRIM8 in HFD-induced glucose metabolism and insulin resistance, TRIM8-HKO mice were generated (Fig.  3A) . As anticipated, mice with a TRIM8 deficiency showed reduced fasting blood glucose levels, fasting serum insulin levels, and HOMA-IR values compared with TRIM8-flox littermate controls after a 12-week HFD challenge ( Fig. 3B-E) . Furthermore, the insulin sensitivity of HFD-fed mice was clearly improved by TRIM8 deletion, as indicated by the GTT and ITT results (Fig. 3F,G) . Examinations of IRS-AKT signaling suggested that insulin signaling activity was enhanced by TRIM8 ablation (Fig. 3H) . Moreover, glycogen content and gluconeogenesis were increased and suppressed, respectively, in the livers of TRIM8-HKO mice compared with control mice (Fig. 3I-K) . Interestingly, the influence of TRIM8 on the physiological phenotype of mice treated with NC was negligible (Figs. 2 and 3). The combined observations of gain-of-function and loss-of-function approaches clearly demonstrate that TRIM8 promotes HFDinduced insulin resistance and glucose metabolic impairment.
HEPATIC TRIM8 EXACERBATES HEPATIC STEATOSIS, INFLAMMATION, AND FIBROSIS
Lipid accumulation in the liver is the most prominent characteristic of NASH and can be promoted by insulin resistance and hepatic inflammation. (20) Sustained HFD elicited dramatic increases in liver weights and the ratio of liver weight to body weight, which were further augmented by TRIM8 up-regulation but blunted in TRIM8-HKO mice compared with controls (Fig. 4A,B) . Hematoxylin and eosin and oil red O staining showed increased lipid accumulation in TRIM8-HTG mice, whereas artificial TRIM8 deficiency led to a decrease in hepatic steatosis after HFD administration (Fig. 4C) . Consistent with these findings, TG, TC, and NEFA contents were significantly increased by TRIM8 (Fig. 4D,E) . Furthermore, the liver dysfunction evaluated by serum ALT, AST, and ALP levels was effectively ameliorated by hepatic TRIM8 deficiency but aggravated by TRIM8 overexpression (Supporting Fig. S2A,B) . Real-time PCR analyses indicated that TRIM8 significantly increased cholesterol synthesis, fatty acid uptake, and fatty acid synthesis but reduced mRNA levels of genes related to cholesterol efflux and fatty acid b-oxidation (Supporting Fig. S2C-J) . The aggravating effect of TRIM8 on lipid accumulation was further confirmed in L02 hepatocytes challenged with palmitate using Bodipy-C16 staining (Supporting Fig. S2K ).
TRIM8-mediated inflammation during hepatic steatosis was demonstrated by the production of cytokines and chemokines in the livers of mice in the indicated groups. The mRNA expression of interleukin-6 (IL-6), tumor necrosis factor-a, and monocyte chemoattractant protein 1 was dramatically elevated; and IL-10 mRNA levels were significantly reduced in TRIM8-HTG mice compared with the levels in NTG controls (Fig. 4F) . In contrast, TRIM8 deletion in the liver alleviated the production of proinflammatory cytokines and chemokines (Fig. 4G) . Consistently, the infiltration of F4/80-positive cells in the liver was remarkably increased by TRIM8 overexpression but decreased by TRIM8 deficiency (Fig. 4H) . Western blotting showed that the classic nuclear factor jB (NF-jB) proinflammatory signaling pathway was dramatically activated by TRIM8 up-regulation, which was demonstrated by the significant increase in the expression of phosphorylated inhibitor of NF-jB kinase subunit b (IKKb) and p-IjBa proteins, accompanied by a decreased IjBa expression (Fig. 4I) . Conversely, the activation of NF-jB signaling was blocked in TRIM8-HKO mice compared with that in the TRIM8-flox controls (Fig. 4I) .
In terms of fibrosis, real-time PCR analysis showed that a 12-week HFD administration triggered a much higher mRNA expression of profibrotic genes, including Col1a1, Tgfb1, Ctgf, and a-Sma, than NC treatment (Fig. 4J) . Histological fibrosis was also developed as evidenced by sirius red and a-smooth muscle actin staining (Fig. 4K) . The increased profibrotic gene expression and histological fibrosis were further enhanced by TRIM8 overexpression but greatly reversed by TRIM8 deficiency (Fig. 4J,K) . Interestingly, TRIM8 showed no significant influence on fatty acid and cholesterol metabolism, inflammation, and fibrosis in NC groups ( Fig. 4; Supporting Fig. S2 ). Together, these results suggest that TRIM8 functions as a potent and positive regulator of hepatic steatosis, inflammation, and fibrosis in response to HFD administration.
TRIM8 DOWN-REGULATION ALLEVIATES INSULIN RESISTANCE AND HEPATIC STEATOSIS IN ob/ob MICE
Given that gene mutation represents another important NASH etiological factor, beyond HFD challenge, (21) we examined the possible roles of TRIM8 in steatohepatitis and metabolic disorders in ob/ob mice by down-regulating TRIM8 expression by infecting mice with AdshTRIM8 (Fig. 5A) . AdshRNA-infected mice served as controls. Similar to the observations in TRIM8-HKO mice, no significant regulation on body weight was found by TRIM8 down-regulation, while TRIM8 knockdown contributed to the significant reductions of fasting blood glucose levels, fasting serum insulin levels, and HOMA-IR index values (Fig. 5B-E) . Additionally, the GTT and ITT results suggested an improved insulin resistance, accompanied by higher glycogen levels in the liver sections from the AdshTRIM8-infected ob/ob mice compared with that in the control group (Fig. 5F-I ). In terms of hepatic steatosis, AdshTRIM8 administration attenuated the increase in liver weight and hepatic lipid accumulation (Fig. 5J-L) . The data obtained from ob/ob mice indicated that the TRIM8 down-regulation may have a potential therapeutic capacity for treating gene deficiency-induced insulin resistance and hepatic steatosis.
TAK1-C-JUN N-TERMINAL KINASE/p38 SIGNALING IS INVOLVED IN TRIM8-REGULATED STEATOHEPATITIS
The potent function of TRIM8 in steatohepatitis and related metabolic disorders prompted us to explore the mechanisms underlying its effects. Accumulating evidence suggests the close participation of mitogenactivated protein kinase (MAPK) signaling in the initiation and progression of NASH and its complications, (22) and thus, our efforts to investigate the mechanisms underlying TRIM8-regulated hepatic steatosis were first focused on MAPK signaling. Figure 6A indicates that all of these 3 subunits of MAPK, i.e., extracellular signal-regulated kinase, c-Jun N-terminal kinase (JNK) and p38, were activated after HFD feeding; however, the expression of phosphorylated JNK and p38, but not phosphorylated extracellular signal-regulated kinase, was significantly influenced by the alterations in TRIM8 expression. Among the classic JNK and p38 members, including apoptosis signal-regulating kinase 1, TAK1, and MAPK/extracellular signal-regulated kinase kinase 1, (23) we found that only the activation of TAK1 responsive to TRIM8 expression changes (Fig. 6B) . Effects of TRIM8 on TAK1-JNK/p38 were substantiated by an in vitro experiment using palmitate-challenged primary hepatocytes transfected with AdTRIM8 or Adsh-TRIM8 (Supporting Fig. S3A ).
We then investigated whether the activation of TAK1 is required for TRIM8-regulated steatohepatitis and metabolic disorders, and thus, a specific inhibitor of TAK1, 5Z-7-OX, was introduced and intraperitoneally injected into TRIM8- overexpressing   FIG. 3 . TRIM8 deficiency significantly ameliorates HFD-induced insulin resistance. (A) Expression of TRIM8 in liver, fat, muscle, and heart samples of TRIM8-flox and TRIM8-HKO mice (n 5 4/group). Expression level of TRIM8 was normalized to b-actin levels. *P < 0.05 versus TRIM8-flox mice. (B-E) Body weights (B), fasting blood glucose levels (C), fasting insulin levels (D), and HOMA-IR values (E) in TRIM8-HKO mice and their littermate controls at the indicated time points in response to HFD feeding (n 5 20-24/group). (F,G) IP GTTs (F) and IP ITTs (G) were performed in TRIM8-flox and TRIM8-HKO mice after HFD feeding for 12 weeks, and the corresponding areas under the curves were calculated (n 5 8-12 mice/group). (H) Expression levels of phosphorylated and total IRS1, AKT, and glycogen synthase kinase 3b in the livers of TRIM8-HKO mice and their littermate controls after 12 weeks of HFD feeding. Expression levels were normalized to b-actin levels. (I) Representative images of periodic acid-Schiffstained liver sections of TRIM8-flox and TRIM8-HKO mice after 12 weeks of HFD feeding (n 5 4/group). (J,K) PEPCK and G6Pase mRNA (J) and protein (K) expression levels in livers of TRIM8-HKO and control mice (n 5 4/group). GAPDH and b-actin served as controls for the PCR and western blot analyses, respectively. (B-L) *P < 0.05 versus the TRIM8-flox/NC group; #P<0.05 versus the TRIM8-flox/HFD group. Abbreviations: GSK, glycogen synthase kinase; PAS, periodic acid-Schiff. mice. The administration of 5Z-7-OX effectively reduced the level of phosphorylated TAK1 in mouse livers (Supporting Fig. S3B ). Phenotypic studies indicated that the specific reduction of TAK1 activation significantly blocked HFD-induced insulin resistance and gluconeogenesis (Fig. 6C-G) . More importantly, the enhanced increases in fasting blood glucose levels, fasting serum insulin levels, and HOMA-IR values ( Fig. 6C-E) , as well as the decreases in insulin sensitivity and glycogen content (Supporting Fig. S3C-G) , by TRIM8 overexpression were largely reversed by TAK1 inhibition. In accord with its function in insulin resistance, 5Z-7-OX almost completely abolished the positive regulation of TRIM8 on liver weight gain, hepatic lipid accumulation, and liver dysfunction (Fig. 6F-I) . A significant suppression of the activation of JNK and IKK as well as increased expression of total IjBa and phosphorylated AKT might account for the neutralizing effect of TAK1 inhibition on TRIM8's role in these pathologies (Fig. 6J) . As it stands, the activation of TAK1 is essential for the function of TRIM8 in regulating insulin resistance and hepatic steatosis.
TRIM8 INTERACTS WITH AND UBIQUITINATES TAK1
Next, we examined how TRIM8 and TAK1 communicate during the development of steatohepatitis, and thus, the binding of TRIM8 to TAK1 was measured. IP assays indicated that TRIM8 physically interacted with TAK1 (Fig. 7A) . Interestingly, TRIM8 overexpression-induced enhancement of its binding to TAK1 only occurred in cytoplasm and requires palmitate stimulation. We found that TRIM8 mainly located at the nucleus at baseline but was translocated into the cytoplasm of hepatocytes where it colocalizes with and binds to TAK1 after palmitate administration (Supporting Fig. S4 ). This provided an explanation for the stress-dependent manner of TRIM8-regulated nonalcoholic fatty liver disease phenotypes. A mapping experiment was performed to further identify domains that were responsible for TRIM8-TAK1 interaction. TRIM8 and TAK1 were both truncated into small fragments according to their respective functional domain distributions (Fig. 7B,C) . Plasmids encoding TRIM8 and TAK1 fragments were transfected into HEK293T cells with hemagglutinin (HA)-TAK1 and HA-TRIM8, respectively. After IP analysis, we observed that the 59-182 amino acid domain had an indispensable role in the binding of TRIM8 to TAK1, while the 301-480 amino acid domain of TAK1 was sufficient for its interaction with TRIM8 (Fig. 7D,E) .
Because TRIM8 has an E3 ligase activity and TAK1 phosphorylation and activation are largely dependent on its ubiquitination, (24, 25) we wondered whether TRIM8 can ubiquitinate TAK1 and facilitate its activation. Therefore, the ubiquitination level of TAK1 in livers of TRIM8-flox, TRIM8-HKO, NTG, and TRIM8-HTG mice were examined after HFD treatment. We found that TRIM8 deficiency dramatically decreased the TAK1 ubiquitination level, which, however, was largely increased by TRIM8 overexpression compared with their corresponding controls (Fig. 7F) . In HEK293T cells cotransfected with TRIM8 and TAK1, the ubiquitination of TAK1 was also dramatically increased compared with cells that were transfected with TAK1 alone (Fig. 7G) . It has been established that the RING domain of TRIM8 is responsible for its E3 ligase activity. (24) After cys15 and cys18 in the RING domain were mutated to alanine (C15A; C18A), TRIM8 lost its ubiquitination activity on TAK1 (Fig. 7H) . The failure of TRIM8 on TAK1 ubiquitination also occurred when the 59-182 amino acid domain of TRIM8 was mutated (Fig. 7I) . In light of these findings, we deduce that the binding capacity and E3 ligase activity of TRIM8 to TAK1 are required for the activation of TAK1 and its downstream signaling. 
TRIM8-REGULATED TAK1 UBIQUITINATION IS ESSENTIAL FOR ITS ROLE IN STEATOHEPATITIS
We next attempted to gain insight into whether the TRIM8-TAK1 interaction and the E3 ligase activity of TRIM8 are required for the regulatory effect of TRIM8 on metabolic disorders. To evaluate the role of the binding capacity of TRIM8 to TAK1 in its functional role, we introduced AdTRIM8-M into mice in parallel with AdTRIM8. AdGFP-infected mice served as controls. Administration of AdTRIM8-M failed to significantly enhance TAK1's phosphorylation compared with that observed in AdTRIM8-injected group (Fig. 8A) . Furthermore, the exacerbated insulin resistance and steatohepatitis by TRIM8 overexpression all disappeared in AdTRIM8-M treated mice (Fig. 8B-M) . To further investigate the requirement of TRIM8 E3 ligase activity in its regulation in steatohepatitis, we injected AdTRIM8(C15A; C18A) mutant to mice that had been treated with HFD for 8 weeks. AdGFPinjected and AdTRIM8-injected mice served as negative and positive controls, respectively. Unlike the AdTRIM8 group, AdTRIM8(C15A; C18A) failed to activate TAK1 and did not show aggravated effect on glucose metabolic disorder, hepatic steatosis, and inflammation compared with the AdGFP group (Supporting Fig. S5 ). Interestingly, AdTRIM8(C15A; C18A) treatment led to a mild attenuation on NASH pathologies (Supporting Fig. S5 ). The improved steatohepatitis by TRIM8 E3 inactivated mutants might be explained by its properties of lacking ubiquitinating capacity but holding the ability to bind to TAK1, which might comprise the binding, ubiquitination, and activation of TAK1 by wild-type TRIM8. Collectively, the interaction with TAK1 and the E3 ligase activity of TRIM8 are indispensable for its exacerbated effects on steatohepatitis and its complications.
Discussion
TRIM8, a ubiquitously expressed E3 ligase, has been shown to be tightly involved in the innate immune response and cell cycle. (11, 12, 26) However, the regulatory effect of TRIM8 on steatohepatitis remains largely unknown. Here, utilizing in vivo and in vitro gain-offunction and loss-of-function approaches, we characterized TRIM8 as a pivotal positive regulator of HFDinduced and gene deficiency-induced steatohepatitis and its related metabolic disorders. Further investigations into the underlying molecular events revealed that TRIM8 directly interacts with and ubiquitinates TAK1, thereby eliciting its autophosphorylation and the hyperactivation of downstream IRS1-AKT, IKKb-NF-jB, and JNK/p38 signaling, which promotes the progression of NASH and its complications.
Hepatic steatosis, insulin resistance, and inflammation are characteristic features/complications of NASH and can mutually enhance each other to form a vicious circle. (27, 28) At the cellular level, insulin signaling, MAPK cascades, and IKK-NF-jB pathway are major links among these pathologies. (29) After long-term HFD feeding, compromised activation of IRS1-AKT induces a sustained activation of FOXO1-PEPCK/the catalytic subunit of G6Pase to promote gluconeogenesis that in turn facilitates hepatic lipogenesis. (30) (31) (32) JNK increases IRS1 phosphorylation at ser307 and inhibits its tyrosine phosphorylation, (33) while p38 targets phosphatase and tensin homolog to inhibit phosphoinositide 3-kinase-AKT cascades. (34) JNK also directly mediates lipid metabolism by targeting peroxisome proliferator-activated receptor target genes and exacerbates inflammation through downstream c-Jun and c-Fos that bind to promoters of proinflammatory mediators. (35) During steatohepatitis, the inflammatory response was mainly driven by NF-jB signaling, which also activates RHOC to inhibit insulin receptor signaling and suppresses cytochrome P450 7A1 to reduce bile acid synthesis. (36) In our study, the capacity of TRIM8 to simultaneously activate all of these molecular events makes targeting TRIM8 a promising therapeutic strategy for NASH treatment.
TAK1, a MAPK kinase kinase protein, has been recognized as a common upstream molecule of MAPK kinase-JNK/p38 and IKK-NF-jB cascades. (25) Using a specific TAK1 inhibitor (5Z-7-OX) that can block both the kinase activity and adenosine triphosphatase activity of TAK1, (37) we demonstrated a beneficial effect of TAK1 inhibition on steatohepatitis improvement and an indispensable role of its activation in TRIM8-exacerbated NASH pathologies. Because TAK1 kinase activity directly contributes to the phosphorylation of downstream factors (25, 38) and adenosine triphosphatase activity is intrinsic for a kinase, (39, 40) both kinase activity and adenosine triphosphatase activity of TAK1 might be involved in its role in steatohepatitis.
Interestingly, Inokuchi-Shimizu et al. (41) and Morioka et al. (42) recently reported that the liver-specific knockout of TAK1 exacerbated hepatic steatosis. This appears to present a paradox concerning the role of TAK1 in steatohepatitis. However, it is important to contrast the TAK1 "inhibition" in our study with the "deletion" in these two previous studies. Remarkably, TAK1 maintains critically important functions in various vital pathophysiological processes, including cell survival, apoptosis, oxidative processes, and immune response. (43, 44) Therefore, total deletion of TAK1 would be expected to impair its fundamental role in body homeostasis and lead to detrimental outcomes. However, it does not mean that TAK1 is a "good guy" with respect to steatohepatitis. Notably, the TAK1 constitutive activation also resulted in spontaneous inflammation and liver cancer. (45) Further, TAK1 can induce hyperactivation of downstream JNK and NFjB signaling, (15, 17, 45, 46) which have been firmly confirmed to promote steatohepatitis development. Thus, an aberrant increase or decrease of TAK1 activity is detrimental to hepatocyte function, and TAK1 should be kept in balance in order to maintain hepatic homeostasis and physiological functions.
A key question that remains to be answered when exploring the mechanisms underlying TRIM8-regulated hepatic steatosis is how TRIM8 activates TAK1. Lys63-linked polyubiquitination is required for the autophosphorylation and activation of TAK1. (47) Coincidentally, TRIM8 has a RING domain that endows it with E3 ligase activity. (48) Here, we report that TRIM8 directly binds to TAK1 and that the RING domain of TRIM8 is mainly responsible for TAK1's ubiquitination. The capacity of TRIM8 to ubiquitinate TAK1 demonstrated in our present study is consistent with the results reported by Li et al. (26) The evidence that TRIM8 failed to aggravate steatohepatitis and its complications when its binding domain was missing or the RING domain was mutated suggests that both the TRIM8-TAK1 interaction and TRIM8's E3 ligase activity are required for its regulatory role.
In conclusion, our present study reports a novel function for TRIM8 in diet-induced and geneinduced NASH. Based on in vivo and in vitro experiments, we clearly identified that TRIM8 significantly exacerbates insulin resistance, hepatic steatosis, inflammation, and fibrosis by directly binding to and ubiquitinating TAK1 that activates downstream JNK/p38 and NF-jB signaling pathways. Treatments that interfere with the TRIM8-TAK1 interaction or TRIM8's E3 ligase activity might prove to be a promising strategy for NASH and metabolic syndrome treatment.
